HBM9161 (HL161)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for HBM9161 (HL161), covering 2023-03-08 to 2026-04-28. Get the full timeline:
Most recent: Clinical Trial Update: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis [Phase 3]